Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BHVN 
Biohaven Pharmaceutical Holding Co Ltd (BHVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: BHVN (3-star) is a WEAK-BUY. BUY since 9 days. Simulated Profits (-12.33%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $48.88
1 Year Target Price $48.88
| 11 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 63.26% | Avg. Invested days 50 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.47B USD | Price to earnings Ratio - | 1Y Target Price 48.88 |
Price to earnings Ratio - | 1Y Target Price 48.88 | ||
Volume (30-day avg) 16 | Beta 3.5 | 52 Weeks Range 12.79 - 55.70 | Updated Date 09/14/2025 |
52 Weeks Range 12.79 - 55.70 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -103.41% | Return on Equity (TTM) -295.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1360251588 | Price to Sales(TTM) - |
Enterprise Value 1360251588 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.19 | Shares Outstanding 105791000 | Shares Floating 88380749 |
Shares Outstanding 105791000 | Shares Floating 88380749 | ||
Percent Insiders 11.55 | Percent Institutions 82.71 |
Upturn AI SWOT
Biohaven Pharmaceutical Holding Co Ltd
Company Overview
History and Background
Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013. It focused on developing therapies for neurological and neuropsychiatric diseases. In 2022, Pfizer acquired Biohaven, but a new company (New Biohaven) was spun out to focus on non-CGRP assets.
Core Business Areas
- Neurology: Focuses on developing and commercializing treatments for neurological disorders.
- Neuropsychiatry: Focuses on developing and commercializing treatments for neuropsychiatric disorders.
- Rare Diseases: Developing Orladeyo for hereditary angioedema and other rare disease therapies.
Leadership and Structure
Vlad Coric, MD, is the Chief Executive Officer of New Biohaven. The organizational structure consists of functional departments focused on research and development, commercialization, and business operations.
Top Products and Market Share
Key Offerings
- Orladeyo (berotralstat): Orladeyo is an oral therapy for hereditary angioedema (HAE). It aims to prevent HAE attacks. Market share is increasing, competition includes Takhzyro (Takeda) and Haegarda (CSL Behring). Revenue in 2023 was approximately $400 million
- Troriluzole: Troriluzole is a glutamate modulator being investigated for obsessive compulsive disorder (OCD). It is currently in clinical development, not yet approved for marketing. Competitors depend on the specific indication, and include SSRIs and other pharmacological options for OCD treatment.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. Neurology and neuropsychiatry are areas of significant unmet medical need.
Positioning
New Biohaven is positioned as a nimble, R&D-focused company targeting neurological and neuropsychiatric disorders, primarily focusing on Orladeyo for revenue while continuing to develop a pipeline of assets.
Total Addressable Market (TAM)
The TAM for neurological and neuropsychiatric disorders is significant, projected to be in the billions of dollars. Biohaven is positioned to capture a portion of this market with its existing and pipeline products.
Upturn SWOT Analysis
Strengths
- Existing Revenue Stream (Orladeyo)
- Strong R&D Pipeline
- Experienced Management Team
- Focus on Unmet Medical Needs
Weaknesses
- Dependence on Orladeyo revenue stream
- High R&D Expenses
- Clinical Trial Risk
- Competition from Established Pharma Companies
Opportunities
- Expansion into New Markets
- Acquisition of Complementary Assets
- Partnerships with Other Companies
- Positive Clinical Trial Results
Threats
- Regulatory Hurdles
- Patent Expiration
- Competition from New Therapies
- Pricing Pressure
Competitors and Market Share
Key Competitors
- TAK
- CSL
Competitive Landscape
Biohaven faces competition from larger, more established pharmaceutical companies with greater resources. Its competitive advantage lies in its focused R&D approach and specialized therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Not applicable for a new company.
Future Projections: Future growth is dependent on Orladeyo sales and the success of the R&D pipeline. Analyst estimates vary depending on pipeline progress.
Recent Initiatives: Focus on expanding Orladeyo market share and advancing clinical trials for pipeline candidates.
Summary
New Biohaven is a pharmaceutical company with an existing revenue stream from Orladeyo and a pipeline of neurological and neuropsychiatric drugs. While possessing specialized products and a dedicated R&D strategy, it faces challenges from larger, more established competitors and clinical trial risks. Success depends on the pipeline and Orladeyo performance, along with effectively handling market challenges and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly. This analysis reflects the current state as of October 26th, 2024.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biohaven Pharmaceutical Holding Co Ltd
Exchange NYSE | Headquaters New Haven, CT, United States | ||
IPO Launch date 2022-09-23 | Chairman & CEO Dr. Vladimir Coric M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 256 | Website https://www.biohaven.com |
Full time employees 256 | Website https://www.biohaven.com | ||
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.